Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction

From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (SDS, BC, ASD, MV); British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, UK (JJVM, PSJ); Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen (RAB, CSPL); University of Wisconsin, Madison (D. DeMets); Duke University Medical Center, Durham, NC (AFH); Yale School of Medicine, New Haven, CT (SEI); St. Luke’s Mid America Heart Institute, University of Missouri, Kansas City, Kansas City (MNK); National Heart Center Singapore and Duke – National University of Singapore, Singapore (CSPL); National University of Cordoba, Cordoba (FM), and Head of Heart Failure, Center for Medical Education and Clinical Research Norberto Quirno, Buenos Aires (JT) ̵[ads1]1; both in Argentina; Northwestern University Feinberg School of Medicine, Chicago (SJS); General University Hospital, Charles University, Prague, Czech Republic (JB); General Clinical Research Center and Department of Cardiology, Taipei Veterans General Hospital and National Yang Ming Chiao Tung University, Taipei, Taiwan (C.-EC); Department of Cardiology, Bellvitge University Hospital and Bellvitge Biomedical Research Institute, University of Barcelona, ​​​​​​L’Hospitalet de Llobregat, Barcelona (JC-C.); George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mureş, Romania (D. Dobreanu); Department of Cardiology, Medical University of Lodz, Lodz, Poland (JD); University of Utah Medical Center, Salt Lake City (JCF); Queretaro Clinical Studies Center, Queretaro, Mexico (MAA-G.); Department of Cardiac Sciences, King Saud University, Riyadh, Saudi Arabia (WAH); Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China (YH); Vesalius Clinic, San Borja, Peru (JWCH); Department of Cardiovascular Diseases, Cardiac Intensive Care Unit, University Hospital Leuven, Leuven, Belgium (SPJ); Department of Non-Invasive Cardiology, National Cardiology Hospital, Sofia, Bulgaria (TK); Kinshukai Higher Secondary School Hospital, Osaka, Japan (MK); Heart and Vascular Center, Semmelweis University, Budapest, Hungary (BM); Montreal Institute of Cardiology, University of Montreal, Montreal (EO), and Division of Cardiac Surgery, St. Louis, Missouri. St. Michael’s Hospital, University of Toronto, Toronto (SV) — both in Canada; cardiovascular department, Clinical Research Institute of Campinas, Campinas, Brazil (JFKS); Department of Heart Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow (SNT); Minneapolis Veterans Affairs Center for Care Delivery and Outcomes Research, University of Minnesota, Minneapolis (OV); Cardiovascular Center, Tam Anh Hospital, Tan Tao University, Tan Duc, Vietnam (VNP); and Late-Stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical Research and Development, AstraZeneca, Gothenburg, Sweden (UW, NZ, EB, DL, MP, AML).